Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Sleep disturbances such as insomnia are not listed as adverse reactions in the UK Summary of Product Characteristics (SmPC)
Developer: Eli Lilly and Company | Administration in Trials: Once-weekly subcutaneous injection First successful Phase 3 trial (TRIUMPH-4, topline Dec 2025): Up to 28.7% average body weight loss at 68 weeks (highest dose) in adults with obesity/overweight and knee osteoarthritis
Potential side effects of GLP-1s include nausea, vomiting, changes in vision, low blood sugar, and, in rare cases, thyroid cancer
They can help you navigate the complexities of managing your health with semaglutide and ensure you achieve the best possible outcomes
US$ 20.28
US$ 20.25
US$ 20.93
US$ 23.39
US$ 22.38
US$ 28.86
